多次复发儿童急性淋巴细胞白血病的突变机制
对29例多次复发儿童急性淋巴细胞白血病患者的97份肿瘤样本进行全基因组测序,发现突变负荷在复发时及每次后续复发时增加,识别出紫外样损伤、APOBEC活性、活性氧、硫嘌呤相关损伤及未知治疗成分等突变过程,其中硫嘌呤暴露是复发时新突变的最主要来源。
要点
- 29例多次复发儿童急性淋巴细胞白血病患者中,28例在复发时突变负荷增加,22例在每次后续复发时增加。
- 识别出紫外样损伤、APOBEC活性、活性氧、硫嘌呤相关损伤及未知治疗成分等突变过程。
- 硫嘌呤暴露是复发时新突变的最主要来源,影响超过一半患者,并在多名患者中导致潜在驱动复发的突变。
核心结论
- 多种突变过程频繁并行作为突出的次级驱动因素,在急性淋巴细胞白血病发展和进展过程中具有动态活性。
研究设计与样本
- 对29例多次复发儿童急性淋巴细胞白血病患者的97份肿瘤样本进行全基因组测序。
主要发现
- 28例患者在复发时突变负荷增加,22例患者在每次后续复发时突变负荷增加。
- 除两种时钟样突变过程外,还识别出紫外样损伤、APOBEC活性、活性氧、硫嘌呤相关损伤及一种未知治疗成分作为诱变驱动因素。
- 突变过程常影响患者较长时间,但也可发生在孤立事件中,提示需要额外触发因素。
- 硫嘌呤暴露是复发时新突变的最突出来源,影响超过一半的研究患者在首次和/或后续复发时,并在多名患者中导致潜在驱动复发的突变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric acute lymphoblastic leukemia (ALL) is marked by low mutational load at initial diagnosis, which increases at relapse. To determine which processes are active in (relapsed) ALL and how they behave during disease progression before and after therapy, we performed whole genome sequencing on 97 tumor samples of 29 multiply relapsed ALL patients. Mutational load increased upon relapse in 28 patients and upon every subsequent relapse in 22 patients. In addition to two clock-like mutational processes, we identified UV-like damage, APOBEC activity, reactive oxygen species, thiopurine-associated damage and an unknown therapy component as drivers of mutagenesis. Mutational processes often affected patients over longer time periods, but could also occur in isolated events, suggesting the requirement of additional triggers. Thiopurine exposure was the most prominent source of new mutations in relapse, affecting over half of the studied patients in first and/or later relapse and causing potential relapse-driving mutations in multiple patients. Our data demonstrate that multiple mutational processes frequently act in parallel as prominent secondary drivers with dynamic activity during ALL development and progression.
引用
- van der Ham CG, Suurenbroek LC, Kleisman MM, et al. Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2024. PMID: 39232206. doi:10.1038/s41375-024-02403-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。